A new study has found that a newly approved drug for leading form of cancer, lung cancer works to improve patient survival rate. The immunotherapy drug is called Tecentriq or atezolizumab. It…
Tag: New Lung Cancer Treatment
New EarlyCDT-Lung Blood Test for Early Detection of Lung Cancer
Thanks to the pioneering new blood test, lung cancer could be detected earlier. This news comes as a fresh hope for lung cancer patients. The main reason behind the increasing number of…
Ramucirumab Injection in Combination with Erlotinib Gets FDA Approval for NSCLC
The Food and Drug Administration (FDA) has approved a 10mg/mL solution for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 mutations….
FDA Approves Tabrecta, First Targeted Therapy for NSCLC
The FDA has approved Tabrecta, Novartis for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. NSCLC is the most common type of lung…
What to Consider Before Getting A Lung Cancer on Marijuana Medication?
Lung cancer is one of the major causes of death, particularly in the US. It has been found that more people die because of it as compared to other types of cancers….
Yale Cancer Center Study Shows Long-Term Survival Benefits for Lung Cancer Patients
As per the global study led by Yale Cancer Center, a tiny amount of biomarker known as PD-L1 can predict long-term survival benefits from pembrolizumab. Pembrolizumab (Keytruda) is one of the first…
Lung Cancer Awareness Month: Latest Researches in Lung Cancer Treatment
Lung Cancer Awareness Month is observed every year in the month of November. It intends to educate public about signs and symptoms of lung cancer. Creating awareness about this deadly disease is…
New Lung Cancer Treatment Approved By NHS Scotland
The Scottish Medicines Consortium (SMC) confirms another immunotherapy treatment in combination with chemotherapy drugs is to be made available on NHS for patients with advanced lung cancer. The decision has been to…